Sagemcom and Com Hem First to Launch Wi-Fi 6 Cable Gateway on Multi-Gigabit Broadband Market
20.11.2019 19:22:00 EET | Business Wire | Press release
THIS NEXT GENERATION HOME GATEWAY ACHIEVES BREATHTAKING PERFORMANCE AND ALLOWS COM HEM CUSTOMERS REACHING MULTI-GIGABIT SPEEDS AND EXPERIENCING ENHANCED CONNECTIVITY.
Designed by Sagemcom, DOCSIS 3.1 eMTA F@st 3896 maximises the distribution over Wi-Fi and 2.5Gbps LAN of the bandwidth coming from the DOCSIS 3.1 network.
This product implements a true Wi-Fi 6 solution, offering better spectrum efficiency, higher network capacity, enhanced user experience and reduced latency on the home networking. It features the latest wireless technologies including OFDMA and 1024QAM modulation and it enables multi-device usages through an efficient bandwidth sharing. It is designed to maximize the throughput for each connected device in the home, to extend the Wi-Fi range and to reduce the power consumption of the connected devices.
In addition, DOCSIS 3.1 eMTA F@st 3896 offers advanced broadband services with Sagemcom Swan®.It is also available with RDK-B and its open partner ecosystem.
DOCSIS 3.1 eMTA F@st 3896 better supports the connected homes with multiple active devices. It accelerates everything that consumers do online today including video streaming, smart home automation, gaming and downloads. It is also ready to support future services and experiences such as 8K video, IA applications, home network security, advanced QoS and more.
"The majority of our customers use wireless connection at home and therefore it is important to us that we have the absolute fastest broadband speeds. Now we are the first Swedish operator to launch WiFi 6, and thanks to that we can offer the fastest speed over WiFi ever achieved among the biggest operators in Sweden. Once again, Com Hem proves that we offer the best surfing experience that you can get in your home", says Joakim Öhrström, Head of Broadband and TV at Com Hem.
About Sagemcom
A French high-tech group of international dimensions, Sagemcom operates on the broadband (set-top boxes, Multi-Gigabit gateways), smart city and Internet of Things (founding member of LoRa Alliance) markets.
With a revenue of 2.1 billion euros, Sagemcom employs 5,500 people on five continents. Sagemcom aims to stay a world leader in communicating terminals with high added value.
www.sagemcom.com
//
www.facebook.com/SagemcomOfficial
//
https://twitter.com/Sagemcom
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191120005687/en/
Contact information
Media
Sylvaine COULEUR
presse@sagemcom.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom